Key facts
- Convergent Therapeutics’s last known valuation is $280.0M.
- It has raised $130.0M across 2 recorded rounds; the latest was Early Stage VC ($22.2M) in Jul 2024.
- Notable investors include RA Capital Management, OrbiMed, Novo Holdings, The Invus Group.
- Convergent Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Aug 2024 ($22.2M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Convergent Therapeutics
Funding rounds
2 roundsAbout Convergent Therapeutics
Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. The company offers a proprietary platform that links humanized monoclonal antibodies targeting prostate-specific membrane antigen (PSMA) with alpha-emitting radionuclides, enabling clinicians to deliver potent, localized radiation into cancer cells while minimizing exposure to healthy tissue.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 10
- Website
- convergentrx.com/
- Ownership
- Privately Held (backing)
Convergent Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convergent Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convergent Therapeutics in its N-PORT filings yet. We sweep new filings monthly.